Krka DD (LTS:0HLK) Piotroski F-Score: 5 (As of Jul. 02, 2026) — 29% Below Median


LTS:0HLK Krka DD LTS:0HLK
84 GF Score
Price €64.80
GF Value €41.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krka DD Piotroski F-Score?

Krka DD LTS:0HLK 84 Piotroski F-Score is 5 as of Jul. 02, 2026, which is 29% below its 10-year median of 7.00. GuruFocus rates LTS:0HLK with a GF Score™ of 84/100 and a GF Value™ of €41.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Krka DD ranks better than 61.57% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Krka DD has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Krka DD's Piotroski F-Score or its related term are showing as below:

LTS:0HLK' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Krka DD was 9. The lowest was 5. And the median was 7.

Krka DD  (LTS:0HLK) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Krka DD Piotroski F-Score Related Terms


Krka DD Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Krka DD's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krka DD Piotroski F-Score Chart

Krka DD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 5.00 8.00 7.00

Krka DD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 7.00 7.00 5.00

LTS:0HLK vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krka DD Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Krka DD's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Krka DD's Piotroski F-Score falls into.


LTS:0HLK
84GF Score
Krka DD LTS:0HLK
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 93.665 + 77.083 + 80.309 + 120.947 = €372 Mil.
Cash Flow from Operations was 81.739 + 128.157 + 146.545 + 95.594 = €452 Mil.
Revenue was 526.427 + 485.487 + 506.997 + 565.774 = €2,085 Mil.
Gross Profit was 302.968 + 277.467 + 298.154 + 342.001 = €1,221 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3095.784 + 3145.164 + 2967.622 + 3042.658 + 3170.527) / 5 = €3084.351 Mil.
Total Assets at the begining of this year (Mar25) was €3,096 Mil.
Long-Term Debt & Capital Lease Obligation was €14 Mil.
Total Current Assets was €2,119 Mil.
Total Current Liabilities was €524 Mil.
Net Income was 123.033 + 59.204 + 75.87 + 152.179 = €410 Mil.

Revenue was 499.273 + 449.244 + 474.882 + 522.114 = €1,946 Mil.
Gross Profit was 286.937 + 252.445 + 274.56 + 304.417 = €1,118 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2857.345 + 3012.11 + 2816.135 + 2849.021 + 3095.784) / 5 = €2926.079 Mil.
Total Assets at the begining of last year (Mar24) was €2,857 Mil.
Long-Term Debt & Capital Lease Obligation was €10 Mil.
Total Current Assets was €2,040 Mil.
Total Current Liabilities was €505 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Krka DD's current Net Income (TTM) was 372. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Krka DD's current Cash Flow from Operations (TTM) was 452. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=372.004/3095.784
=0.12016471

ROA (Last Year)=Net Income/Total Assets (Mar24)
=410.286/2857.345
=0.14358994

Krka DD's return on assets of this year was 0.12016471. Krka DD's return on assets of last year was 0.14358994. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Krka DD's current Net Income (TTM) was 372. Krka DD's current Cash Flow from Operations (TTM) was 452. ==> 452 > 372 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=13.726/3084.351
=0.00445021

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=10.356/2926.079
=0.00353921

Krka DD's gearing of this year was 0.00445021. Krka DD's gearing of last year was 0.00353921. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2118.774/523.723
=4.04560044

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2039.544/505.044
=4.03834913

Krka DD's current ratio of this year was 4.04560044. Krka DD's current ratio of last year was 4.03834913. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Krka DD's number of shares in issue this year was 32.777. Krka DD's number of shares in issue last year was 30.62. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1220.59/2084.685
=0.58550333

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1118.359/1945.513
=0.57484016

Krka DD's gross margin of this year was 0.58550333. Krka DD's gross margin of last year was 0.57484016. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=2084.685/3095.784
=0.67339485

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1945.513/2857.345
=0.68088138

Krka DD's asset turnover of this year was 0.67339485. Krka DD's asset turnover of last year was 0.68088138. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Krka DD has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Krka DD (LTS:0HLK) has a Piotroski F-Score of 5 as of Jul. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Krka DD and its competitors. This is 29% below median its historical median of 7.00. Over the past decade, Krka DD's Piotroski F-Score has ranged from 5.00 to 9.00. According to the industry distribution chart, Krka DD ranks #377 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is Krka DD's Piotroski F-Score too high?
Krka DD's current Piotroski F-Score of 5 is 29% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Krka DD's value of 5 is 0% at this industry median. Based on the distribution chart, Krka DD ranks #377 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Krka DD has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #377 out of 981 companies for Piotroski F-Score. This puts Krka DD in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Krka DD's value of 5 is 0% at this benchmark. Historically, Krka DD's own Piotroski F-Score has ranged from 5.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Krka DD has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Piotroski F-Score is 5, which is 29% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.99, compared to a current price of €64.80 — trading 54.3% above its estimated fair value. The current Piotroski F-Score is 5, which is 29% below median its 10-year median of 7.00 and 0% at the Drug Manufacturers industry median of 5.00. Krka DD's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current Piotroski F-Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krka DD (LTS:0HLK) Overvalued in 2026?

Based on GuruFocus' analysis, Krka DD stock appears to be overvalued. The current stock price of €64.80 is trading 54.3% above its estimated GF Value™ of €41.99. GuruFocus considers Krka DD to be Significantly Overvalued.

Key valuation signals for LTS:0HLK:

  • Piotroski F-Score: 5 (29% below median its 10-year median of 7.00)
  • GF Value™: €41.99 vs. price of €64.80 (54.3% above fair value)
  • GF Score™: 84/100 with 6 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#377 of 981)

No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krka DD Business Description

Address Smarjeska Cesta 6, Novo Mesto, SVN, 8501
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
84GF Score

Get the complete analysis for LTS:0HLK

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.80
Price
€41.99
GF Value